National Institute of Neurological Disorders and Stroke Amended; Notice of Meeting, 47218 [2011-19813]
Download as PDF
sroberts on DSK5SPTVN1PROD with NOTICES
47218
Federal Register / Vol. 76, No. 150 / Thursday, August 4, 2011 / Notices
allows inducible expression of RORg
upon addition of doxycycline. Upon its
induction RORg binds to the RORE in
the luciferase reporter plasmid and
induces luciferase. This system can be
used to identify RORg antagonists. This
system has been tested successfully in
1536-well plate high throughput
analysis.
Potential Commercial Applications:
Identification of therapeutic compounds
to treat asthma, inflammation, and
various autoimmune diseases such as
osteoarthritis, multiple sclerosis.
Competitive Advantages: Novel and
unique system to screen and identify
chemical and drugs for their RORg
antagonistic activity.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Inventors: Drs. Yukimasa Takeda and
Anton M. Jetten (NIEHS).
Publications:
1. Jetten AM. Retinoid-related
receptors (RORs): Critical roles in
development, immunity, circadian
rhythm, and cellular metabolism. Nucl
Recept Signal. 2009;7:1–32. [PMID:
19381306].
2. Yang XO, et al. T helper 17 lineage
differentiation is programmed by
orphan receptors ROR alpha and ROR
gamma. Immunity 2008 Jan;28(1):29–39.
[PMID: 18164222].
3. Kurebayashi S, et al. Retinoidrelated orphan receptor gamma
(RORgamma) is essential for lymphoid
organogenesis and controls apoptosis
during thymopoiesis. Proc Natl Acad
Sci USA. 2000 Aug 29;97(18):10132–
10137. [PMID:10963675].
Intellectual Property: HHS Reference
No. 253–2010/0—Research Tool. Patent
protection is not being pursued for this
technology.
Related Technology: HHS Reference
No. E–222–2009/0—RORgamma (RORC)
Deficient Mice Which Are Useful for the
Study of Lymph Node Organogenesis
and Immune Responses (Dr. Anton M.
Jetten, NIEHS).
Licensing Contact: Suryanarayana
(Sury) Vepa, PhD; 301–435–5020;
vepas@mail.nih.gov.
Collaborative Research Opportunity:
The NIEHS, Laboratory of Respiratory
Biology, Cell Biology Group, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize retinoid-related orphan
receptors (RORs) function in chronic
diseases. For collaboration
opportunities, please contact Elizabeth
M. Denholm, PhD at
denholme@niehs.nih.gov.
VerDate Mar<15>2010
17:29 Aug 03, 2011
Jkt 223001
Dated: July 27, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–19817 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke Amended; Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Neurological Disorders and Stroke
Special Emphasis Panel, August 2, 2011,
9 a.m. to August 2, 2011, 3 p.m.,
National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 which
was published in the Federal Register
on July 20, 2011, 76FFRN43333–43334.
The meeting has been rescheduled for
August 23, 2011. The time and meeting
location remain the same. The meeting
is closed to the public.
Dated: July 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–19813 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Training Grant Review.
Date: August 24, 2011.
Time: 10:30 a.m. to 4:30 p.m.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Roy L. White, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7176, Bethesda, MD 20892–7924, 301–435–
0310, whiterl@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Ancillary Studies Review.
Date: August 26, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Tony L. Creazzo, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7180, Bethesda, MD 20892–7924, 301–435–
0725, creazzotl@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Research Dissemination and Implementation
Grants.
Date: August 26, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Keith A. Mintzer, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7186,
Bethesda, MD 20892–7924, 301–435–0280,
mintzerk@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–19796 Filed 8–3–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\04AUN1.SGM
04AUN1
Agencies
[Federal Register Volume 76, Number 150 (Thursday, August 4, 2011)]
[Notices]
[Page 47218]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-19813]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke Amended;
Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute of Neurological Disorders and Stroke Special Emphasis Panel,
August 2, 2011, 9 a.m. to August 2, 2011, 3 p.m., National Institutes
of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD
20852 which was published in the Federal Register on July 20, 2011,
76FFRN43333-43334.
The meeting has been rescheduled for August 23, 2011. The time and
meeting location remain the same. The meeting is closed to the public.
Dated: July 29, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-19813 Filed 8-3-11; 8:45 am]
BILLING CODE 4140-01-P